Journal of cancer research and clinical oncology
-
J. Cancer Res. Clin. Oncol. · Jan 2016
Comparative StudyComparing RECIST with EORTC criteria in metastatic bladder cancer.
To compare RECIST and EORTC criteria in an evaluation of response to therapy in metastatic bladder cancer and to assess their influence on decisions to administer additional therapy. ⋯ A group of patients that had been determined as having a SD according to RECIST criteria were grouped as PR and/or CR according to EORTC criteria. Additional chemotherapy protocols can be used in second-line chemotherapy and/or cisplatin-resistant patients, according to RECIST criteria. In evaluating the response to first-line chemotherapy for metastatic bladder cancer, EORTC criteria, using (18)FDG-PET/CT scans, can be considered as a more applicable and accurate diagnostic tool. The anatomical findings obtained through imaging methods and from functional/metabolic data obtained by PET/CT can be useful in the planning of second- or third-line chemotherapy, and a high accuracy in re-staging can spare patients from second-line or even third-line chemotherapy.
-
J. Cancer Res. Clin. Oncol. · Jan 2016
Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
The aim of this study was to identify the uptake rate of risk-reducing salpingo-oophorectomy (RRSO) and the factors affecting this rate among female BRCA1 or BRCA2 mutation carriers at the National Cancer Center of Korea. ⋯ The uptake rate of RRSO among BRCA1/2 mutation carriers was affected by the presence of amenorrhea and consultation with gynecologic oncologists. Gynecologic oncologists with clinical experience with ovarian cancer should play a major role in aiding carriers' decision-making concerning RRSO.
-
J. Cancer Res. Clin. Oncol. · Jan 2016
The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up.
To investigate whether an association exists between a history of fertility treatments and future risk of female malignancies. ⋯ IVF treatments pose a significant risk of subsequent long-term ovarian and uterine cancer.